Table 4:

Overall Response Rates and Duration of Response of Patients in SCLC Cohort in Study B-005

Investigator Assessed Response	All SCLC N=105	Sensitive CTFI ≥ 90 days N=60	Resistant CTFI < 90 days N=45
Overall Response Rate (95% CI)	35% (26, 45)	45% (32, 58)	22% (11, 37)
Complete response, n (%)	0 (0)	0 (0)	0 (0)
Partial response, n (%)	37 (35)	27 (45)	10 (22)
Median DOR months (95% CI)	5.3 (4.1, 6.4)	6.2 (3.5, 7.3)	4.7 (2.6, 5.6)
≥ 6 months DOR, n (%)	13 (35)	12 (44)	1 (10)
IRC Assessed Response
Overall Response Rate (95% CI)	30.5% (22 40)	43% (31, 57)	13% (5, 27)
Complete response, n (%)	0 (0)	0 (0)	0 (0)
Partial response, n (%)	32 (30)	26 (43)	6 (13)
Median DOR months (95% CI)	5.1 (4.9, 6.4)	5.3 (4.9, 7.0)	4.8 (2.4, 5.3)
≥ 6 months DOR, n (%)	8 (25)	8 (31)	0 (0)

Abbreviations: CI: confidence interval; CTFI: chemotherapy-free interval; DOR: duration of response; IRC: independent review committee; SCLC: small cell lung cancer.

Source: ZEPZELCA (lurbinectedin) [package insert] (Ref. 11)